<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39432992</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>26</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>20</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Anti-RBD IgG dynamics following infection or vaccination.</ArticleTitle><Pagination><StartPage>126464</StartPage><MedlinePgn>126464</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2024.126464</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(24)01146-0</ELocationID><Abstract><AbstractText>Identifying parameters influencing SARS-CoV-2 antibody dynamics post infection or vaccination is crucial for refining vaccination strategies. In a longitudinal analysis of 1340 samples from 375 healthcare workers, we characterized peak serological response and IgG half-life. Peak antibody titers post 2 vaccine doses were ∼ 20 times higher than natural infection; conversely, infected individuals had extended antibody half-life. Clinical and demographical factors such as BMI, age and smoking shaped peak response without affecting anti-RBD IgG half-life. A third mRNA vaccine dose increased peak antibody titers and prolonged half-life compared to the second dose. These findings underscore the diverse kinetics of SARS-CoV-2 antibody responses, which is influenced by immunization type/number and clinical factors.</AbstractText><CopyrightInformation>Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Harrache</LastName><ForeName>Amira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biostatistics Department, Hospices Civils de Lyon, Lyon France. CNRS, UMR 5558, University of Lyon, Biometrics and Evolutionary Biology Laboratory, Biostatistics-Health Team, 69100 Villeurbanne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saker</LastName><ForeName>Kahina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Joint Research Unit Hospices Civils of Lyon-bioMérieux, Lyon Sud Hospital, Hospices Civils de Lyon, 69310 Pierre-Bénite, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mokdad</LastName><ForeName>Bouchra</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Joint Research Unit Hospices Civils of Lyon-bioMérieux, Lyon Sud Hospital, Hospices Civils de Lyon, 69310 Pierre-Bénite, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Generenaz</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Joint Research Unit Hospices Civils of Lyon-bioMérieux, Lyon Sud Hospital, Hospices Civils de Lyon, 69310 Pierre-Bénite, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saade</LastName><ForeName>Carla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Joint Research Unit Hospices Civils of Lyon-bioMérieux, Lyon Sud Hospital, Hospices Civils de Lyon, 69310 Pierre-Bénite, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pons</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Joint Research Unit Hospices Civils of Lyon-bioMérieux, Lyon Sud Hospital, Hospices Civils de Lyon, 69310 Pierre-Bénite, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fassier</LastName><ForeName>Jean-Baptiste</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Occupational Health and Medicine Department, Hospices Civils de Lyon, 69002 Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>COVID-SER Study group</CollectiveName></Author><Author ValidYN="Y"><LastName>Bal</LastName><ForeName>Antonin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Virology Laboratory, Institute of Infectious Agents, Laboratory associated with the National Reference Centre for Respiratory Infection Viruses, Hospices Civils de Lyon, IAI, North Biology Centre, North Hospital Group, 69004 Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trabaud</LastName><ForeName>Mary-Anne</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Virology Laboratory, Institute of Infectious Agents, Laboratory associated with the National Reference Centre for Respiratory Infection Viruses, Hospices Civils de Lyon, IAI, North Biology Centre, North Hospital Group, 69004 Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabilloud</LastName><ForeName>Muriel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biostatistics Department, Hospices Civils de Lyon, Lyon France. CNRS, UMR 5558, University of Lyon, Biometrics and Evolutionary Biology Laboratory, Biostatistics-Health Team, 69100 Villeurbanne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abichou-Klich</LastName><ForeName>Amna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biostatistics Department, Hospices Civils de Lyon, Lyon France. CNRS, UMR 5558, University of Lyon, Biometrics and Evolutionary Biology Laboratory, Biostatistics-Health Team, 69100 Villeurbanne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trouillet-Assant</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Joint Research Unit Hospices Civils of Lyon-bioMérieux, Lyon Sud Hospital, Hospices Civils de Lyon, 69310 Pierre-Bénite, France. Electronic address: sophie.trouillet-assant@chu-lyon.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2 vaccine</Keyword><Keyword MajorTopicYN="N">antibody peak</Keyword><Keyword MajorTopicYN="N">clinical factors</Keyword><Keyword MajorTopicYN="N">half-life</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Sophie Trouillet-Assant reports financial support was provided by Agence Nationale de Recherches sur le Sida et les Hépatites Virales. Sophie Trouillet-Assant reports a relationship with National Agency for Research on AIDS and Viral Hepatitis that includes: funding grants. Laurence Generenaz and Sylvie Pons are employees of bioMérieux SA, an in vitro diagnostic company. bioMérieux kindly provided all the serological kits. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>4</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>4</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>18</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39432992</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2024.126464</ArticleId><ArticleId IdType="pii">S0264-410X(24)01146-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle>